Latest Intelligence on Central Nervous System

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

APA 2010: new long-term data confirm potential of depot formulations

Bringing improved patient compliance, depot formulations tackle a crucial unmet need in schizophrenia and the FDA approval of Invega Sustenna and Zyprexa Relprevv represent important steps to improve the transparency of compliance. At this year's American Psychiatric Association meeting, both Johnson & Johnson and Eli Lilly presented data of these depots' long-term efficacy and safety.

Published By Datamonitor
10 Jun 2010
Expert View
Expert View

APA 2010: unmet needs in major depressive disorder remain key

Key themes presented in the field of major depressive disorder at this year's American Psychiatric Association annual meeting included treatment-resistant depression, transcranial magnetic stimulation and adjunctive use of antipsychotics. While no new clinical trial data were presented, those that were provide an interesting insight into the strategies of a number of major pharmaceutical players.

Published By Datamonitor
10 Jun 2010
Expert View
Expert View

APA 2011: addressing treatment resistance remains the key theme for depression

Datamonitor recently attended the 164th Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii, which ran over May 14-18, 2011. Of particular interest were the promising data presented for several agents in late-stage development for treatment-resistant depression. Below are the highlights of the conference's coverage of developmental depression drugs.

Published By Datamonitor
27 May 2011
Expert View
Expert View

APA 2011: advances and challenges in developing psychiatric services in China

With patents of several psychiatric drugs set to expire in the US and EU over 2011-12, key players are increasingly seeking to expand their geographical reach to growth markets in an attempt to extend revenue streams. In apparent recognition of this trend, the 164th Annual Meeting of the American Psychiatric Association included a forum dedicated to Chinese psychiatric services and research.

Published By Datamonitor
27 May 2011
Expert View
Expert View

APA 2011: future directions for research in substance dependence and autism outlined

Adjunctive therapies in depression, schizophrenia, and attention deficit hyperactivity disorder were key themes at the 164th American Psychiatric Association Annual Meeting. However, three conditions characterized by a high level of unmet need did not go overlooked: bipolar disorders, substance dependence, and autism.

Published By Datamonitor
27 May 2011
Expert View
Expert View

APA 2011: long-term data support new entrants in increasingly competitive schizophrenia market

Datamonitor recently attended the 164th Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii, which ran over May 14-18, 2011. The focus in schizophrenia was on long-term data for new market entrants and treatment adherence, with limited new clinical trial data for pipeline candidates.

Published By Datamonitor
26 May 2011
Expert View
Expert View

APA 2011: Shire and Shionogi position non-stimulants as adjunct therapies for the management of ADHD

Datamonitor attended the 164th Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii, which ran over May 14-18, 2011. In attention deficit hyperactivity disorder, the promotion of recent market entrants Intuniv and Kapvay took precedence, with presentations of post-marketing long-term clinical data.

Published By Datamonitor
26 May 2011
Expert View
Expert View

APA 2012: cariprazine fails to offer a therapeutic breakthrough

Forest and Gedeon's cariprazine is a pharmacologically unique atypical antipsychotic in Phase III development for both schizophrenia and bipolar mania. Data presented at APA 2012 hint that while cariprazine appears to be effective in both indications, its tolerability and failure to address the broader bipolar depression patient population will hinder uptake.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: diagnostic overhaul will shape psychiatry drug markets

The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: Forest's latest antidepressants will have diverging fortunes

Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.

Published By Datamonitor
15 May 2012

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.